Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class

The Menagerie of Human Lipocalins: A Natural Protein Scaffold for Molecular Recognition of Physiological Compounds

(2015) André Schiefner et al.   ACCOUNTS OF CHEMICAL RESEARCH

Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins

(2013) A. Richter et al.   FEBS LETTERS

Antibodies to watch in 2014

(2013) Janice M Reichert   mAbs

A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity

(2013) Shane A. Olwill et al.   MOLECULAR CANCER THERAPEUTICS

First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors

(2013) Klaus Mross et al.   PLoS One

Highly potent VEGF-A-antagonistic DARPins as anti-angiogenic agents for topical and intravitreal applications

(2012) Andreas Stahl et al.   ANGIOGENESIS

Combinatorial Design of an Anticalin Directed against the Extra-Domain B for the Specific Targeting of Oncofetal Fibronectin

(2012) Michaela Gebauer et al.   JOURNAL OF MOLECULAR BIOLOGY

Pharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies

(2011) Stacey D Finley et al.   BMC Systems Biology

Endothelial cell activation in a VEGF-A gradient: Relevance to cell fate decisions

(2010) Ann Akeson et al.   MICROVASCULAR RESEARCH

Development trends for human monoclonal antibody therapeutics

(2010) Aaron L. Nelson et al.   NATURE REVIEWS DRUG DISCOVERY

A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity

(2009) Daniel A. Breustedt et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Bevacizumab induced reversible thrombocytopenia in a patient with recurrent high-grade glioma: a case report

(2009) Ticiana Leal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

High-Affinity Recognition of Lanthanide(III) Chelate Complexes by a Reprogrammed Human Lipocalin 2

(2009) Hyun Jin Kim et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies

(2009) D. Schonfeld et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice

(2008) T. MEYER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS